uniQure (NASDAQ:QURE) CEO Sells $334,800.00 in Stock

Posted by Stanley Muller on Jun 29th, 2026

uniQure N.V. (NASDAQ:QURE – Get Free Report) CEO Matthew Kapusta sold 6,696 shares of the company’s stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $50.00, for a total value of $334,800.00. Following the completion of the sale, the chief executive officer owned 519,227 shares of the company’s stock, valued at $25,961,350. This represents a 1.27% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

uniQure Price Performance

Shares of QURE opened at $47.51 on Monday. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 1 year low of $8.73 and a 1 year high of $71.50. The stock has a market cap of $3.00 billion, a P/E ratio of -13.65 and a beta of 0.98. The stock’s 50-day moving average price is $27.84 and its two-hundred day moving average price is $23.03.

uniQure (NASDAQ:QURE – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. The company had revenue of $3.56 million during the quarter, compared to analyst estimates of $5.21 million. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%. On average, equities analysts predict that uniQure N.V. will post -3.65 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on QURE. The Goldman Sachs Group upped their target price on shares of uniQure from $14.00 to $46.00 and gave the company a “neutral” rating in a research note on Thursday, June 18th. HC Wainwright reissued a “buy” rating on shares of uniQure in a report on Thursday, June 18th. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. Barclays raised uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $25.00 to $65.00 in a research note on Thursday, June 18th. Finally, Chardan Capital lifted their target price on uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Twelve research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $61.67.

Get Our Latest Stock Report on uniQure

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. increased its position in shares of uniQure by 5.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock worth $243,000 after acquiring an additional 533 shares in the last quarter. Arizona State Retirement System lifted its position in uniQure by 6.0% in the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 627 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in uniQure by 21.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 650 shares during the period. FNY Investment Advisers LLC boosted its stake in uniQure by 76.7% in the 3rd quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 718 shares during the period. Finally, CIBC Private Wealth Group LLC bought a new position in uniQure during the 3rd quarter worth about $50,000. Institutional investors own 78.83% of the company’s stock.

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.